Trypanosoma cruzi: Activity of heterocyclic cationic molecules in vitro

Experimental Parasitology

Volumn 123, Issue 1, 2009, Pages 73-80

  Pacheco, Michele Gabriele de Oliveira ^a   Silva, Cristiane França da ^a   Souza, Elen Mello de ^a   Batista, Marcos Meuser ^a   Silva, Patrícia Bernardino da ^a   Kumar, Arvind ^b   Stephens, Chad E ^b   Boykin, David W ^b   Soeiro, Maria de Nazaré C ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Chagas disease; Diamidines; Trypanosoma cruzi

Indexed keywords

AMIDINOHYDRAZONE; ANTIPARASITIC AGENT; ARYLIMIDAMIDE; DB 1080; DB 1195; DB 1196; DB 1345; DB 613A; DB 824; DIAMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; CHAGAS DISEASE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

AMIDINES; ANIMALS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS; INHIBITORY CONCENTRATION 50; PARASITIC SENSITIVITY TESTS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; VERO CELLS;

TRYPANOSOMA CRUZI;

EID: 68049148349     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2009.06.004     Document Type: Article

References (33)

1. Barrett M.P., Burchmore R.J., Stich A., Lazzari J.O., Frasch A.C., Cazzulo J.J., and Krishna S. The trypanosomiases. The Lancet 362 (2003) 1469-1480
2. Bouteille B., Oukem O., Bisser S., and Dumas M. Treatment perspectives for human African trypanosomiasis. Fundamental & Clinical Pharmacology 17 (2003) 171-181
3. Bray P.G., Barrett M.P., Ward S.A., and De Koning H.P. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends in Parasitology 19 (2003) 232-239
4. Castro E., Gironés N., Bueno J.L., Carrión J., Lin L., and Fresno M. The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 47 (2007) 434-441
5. da Silva C.F., Batista M.M., Batista D.daG., de Souza E.M., da Silva P.B., de Oliveira G.M., Meuser A.S., Shareef A.R., Boykin D.W., and Soeiro M.N. Trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi: in vitro and in vivo studies. Antimicrobial Agents Chemotherapy 52 (2008) 3307-3314
6. De Souza E.M., Lansiaux A., Bailly C., Wilson W.D., Hu Q., Boykin D.W., Batista M.M., Araújo-Jorge T.C., and Soeiro M.N. Phenyl substitution of furamidine markedly potentiates its anti-parasitic activity against Trypanosoma cruzi and Leishmania amazonensis. Biochemical Pharmacology 68 (2004) 593-600
7. De Souza E.M., Oliveira G.M., Boykin D.W., Kumar A., Hu Q., and Soeiro M.N. Trypanocidal activity of the phenyl-substituted analogue of furamidine DB569 against Trypanosoma cruzi infection in vivo. Journal of Antimicrobial Chemotherapy 58 (2006) 610-614
8. De Souza E.M., Menna-Barreto R., Araujo-Jorge T.C., Kumar A., Hu Q., Boykin D.W., and Soeiro M.N. Antiparasitic activity of aromatic diamidines is related to apoptosis-like death in Trypanosoma cruzi. Parasitology 133 (2006) 75-79
9. De Souza E.M., Melo G.M., Soeiro M.N., and Boykin D.W. Electrocardiographic findings in acutely and chronically Trypanosoma cruzi-infected mice treated by a phenyl-substituted analogue of furamidine DB569. Drug Targets Insights 2 (2007) 61-69
10. Dias J.C. Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusion Chagas disease: historical aspects, present situation, and perspectives. Memórias do Instituto Oswaldo Cruz 102 (2007) 11-18
11. Fairlamb A.H. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends in Parasitology 9 (2003) 488-494
12. Givens M.D., Stringfellow D.A., Dykstra C.C., Riddell K.P., Galik P.K., Sullivan E., Robl J., Kasinathan P., Kumar A., and Boykin D.W. Prevention and elimination of bovine viral diarrhea virus infections in fetal fibroblast cells. Antiviral Research 64 (2004) 113-118
13. Hopkins K., Wilson W.D., Bender B.C., McCurdy D.R., Hall J.E., Tidwell R.R., Kumar A., Bajic M., and Boykin D.W. Extended aromatic furan amidino derivatives as anti-Pneumocystis carinii agents. Journal of Medicinal Chemistry 41 (1998) 3872-3878
14. Meirelles M.N., de Araújo Jorge T.C., and de Souza W. Interaction of Trypanosoma cruzi with macrophages in vitro: dissociation of the attachment and internalization phases by low temperature and cytochalasin B. Zeitschrift für Parasitenkunde 68 (1982) 7-14
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal Immunology Methods 65 (1983) 55-63
16. Piron M., Vergés M., Muñoz J., Casamitjana N., Sanz S., Maymó R.M., Hernández J.M., Puig L., Portús M., Gascón J., and Sauleda S. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 48 (2008) 1862-1868
17. Rocha M.O., Teixeira M.M., and Ribeiro A.L. An update on the management of Chagas cardiomyopathy. Expert Review of Anti-Infective Therapy 5 (2007) 727-743
18. Rodrigues Coura R.J., and de Castro S.L. A critical review on Chagas' disease chemotherapy. Memórias do Instituto Oswaldo Cruz 97 (2002) 3-24
19. Rowland E.C., Moore-Lai D., Seed J.R., Stephens C.E., and Boykin D.W. Inhibition of in vitro intracellular growth of Trypanosoma cruzi by dicationic compounds. Journal Parasitology 89 (2003) 1078-1080
20. Santa-Rita R.M., Barbosa H.S., and de Castro S.L. Ultrastructural analysis of edelfosine-treated trypomastigotes and amastigotes of Trypanosoma cruzi. Parasitology Research 100 (2006) 187-190
21. Schoenbach E.B., and Greenspan E.M. The pharmacology, mode of action and therapeutic potentialities of stilbamidine, pentamidine, propamidine and other aromatic diamidines-a review. Medicine (Baltimore) 27 (1948) 327-377
22. Silva C.F., Batista M.M., Mota R.A., de Souza E.M., Meirelles M.N., Stephens C.E., Som P., Boykin D.W., and Soeiro M.N. Activity of "reversed" diamidines against Trypanosoma cruzi in vitro. Biochemical Pharmacology 73 (2007) 1939-1946
23. Silva C.F., Meuser M.B., De Souza E.M., Meirelles M.N., Stephens C.E., Som P., Boykin D.W., and Soeiro M.N. Cellular effects of reversed amidines on Trypanosoma cruzi. Antimicrobial Agents Chemotherapy 51 (2007) 3803-3809
24. Soeiro M.N.C., de Castro S.L., de Souza E.M., Batista D.G.J., Silva C.F., and Boykin D.W. Diamidines activity upon trypanosomes: the state of the art. Current Molecular Pharmacology 1 (2008) 151-161
25. Soeiro M.N.C., De Souza E.M., and Boykin D.W. Anti-parasitic activity of aromatic diamidines and their patented literature. Expert Opnion Patent Literature 17 (2007) 1-13
26. Soeiro M.N.C., and De Castro S.L. Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opinion on Therapeutic Targets 13 (2008) 105-121
27. Sosa-Estani S., and Segura E.L. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Current Opinion in Infectious Diseases 19 (2006) 583-587
28. Stephens C.E., Brun R., Salem M.M., Werbovetz K.A., Tanious F., Wilson W.D., and Boykin D.W. The activity of diguanidino and 'reversed' diamidino 2, 5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani. Bioorganic & Medicinal Chemistry Letters 13 (2003) 2065-2069
29. Stephens C.E., Tanious F., Kim S., Wilson W.D., Schell W.A., Perfect J.R., Franzblau S.G., and Boykin D.W. Diguanidino and "reversed" diamidino 2, 5-diarylfurans as antimicrobial agents. Journal Medicinal Chemistry 44 (2001) 1741-1748
30. Tidwell R.R., and Boykin D.W. Minor groove binders as antimicrobial agents. Small molecule DNA and RNA binder: synthesis to nucleic acid complexes (2003), Wiley-VCH, New York 16-460
31. Viotti R., and Vigliano C. Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert Review Anti Infective Therapy 5 (2007) 717-726
32. Werbovetz K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Current Opinion Investigational Drugs 7 (2006) 147-157
33. WHO: The world health report, 2002. World Health Organization, Geneva.